8-K: Repare Therapeutics Acquired by XenoTherapeutics for Cash, CVRs

Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., offering shareholders an estimated US$1.82 per share plus contingent value rights.

Summary

• Repare Therapeutics Inc. has entered into a definitive arrangement agreement to be acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, Xeno).
• Shareholders will receive an estimated cash payment of US$1.82 per common share at closing, based on current estimates of the Closing Net Cash Amount.
• Each shareholder will also receive one non-transferable contingent value right (CVR) for each common share, entitling them to certain future cash payments.
• CVRs include 100% of certain additional receivables within 90 days post-closing (net of permitted deductions).
• CVRs provide a percentage of net proceeds from existing partnerships (Bristol-Myers Squibb, Debiopharm, DCx Biotherapeutics), ranging from 90% for the first two years post-closing, decreasing to 75% from the 6th to 10th anniversary of closing.
• CVRs also include 100% of net proceeds from licenses or dispositions of RP-1664, RP-3500 (Camonsertib), or other programs if entered into prior to closing, and 100% for the Polq program (RP-3467) if negotiations began pre-closing.
• Additionally, CVRs include 50% of net proceeds from any other licenses or dispositions of product candidates and/or intellectual property occurring within 10 years following the closing date if entered into after closing.
• The transaction is expected to close in the first quarter of 2026 and requires approval from 66 2/3% of Repare shareholders, a majority of votes excluding certain interested parties, and the Superior Court of Quebec.
• Upon completion, Repare will become a privately held company, and its common shares are expected to be delisted from the Nasdaq Global Select Market.
• Repare reported cash, cash equivalents, and marketable securities of $112.6 million as of September 30, 2025, an increase from $109.5 million at June 30, 2025.
• For the three months ended September 30, 2025, revenue from collaboration agreements was $11.6 million, and the company reported a net income of $3.3 million, or $0.08 diluted per share.
• For the nine months ended September 30, 2025, revenue from collaboration agreements was $11.9 million, and the company reported a net loss of $43.5 million, or $1.02 per share.

Sentiment

Score: 7

Explanation: The acquisition provides immediate cash value and potential future upside through CVRs for shareholders, while the company's Q3 financial performance showed significant improvement with a return to net income and reduced expenses. However, the overall nine-month performance still reflects a substantial loss, and the delisting means loss of public market access.

Positives

• The acquisition provides an immediate cash payment to shareholders, estimated at US$1.82 per share.
• Shareholders retain potential future upside through CVRs tied to existing partnerships and future monetization of pipeline assets for up to 10 years.
• The Board of Directors, following an independent Transaction Committee's unanimous recommendation, unanimously approved the transaction, indicating strong internal support.
• Cash, cash equivalents, and marketable securities increased to $112.6 million as of September 30, 2025, from $109.5 million at June 30, 2025.
• Repare achieved a net income of $3.3 million ($0.08 diluted EPS) for Q3 2025, a significant improvement from a net loss of $34.4 million ($0.81 diluted EPS) in Q3 2024.
• Research and development expenses, net of tax credits, decreased substantially to $7.5 million in Q3 2025 from $28.4 million in Q3 2024.
• General and administrative expenses also decreased to $4.5 million in Q3 2025 from $6.4 million in Q3 2024.
• Positive initial topline safety, tolerability, and early efficacy data were presented for RP-1664 from its Phase 1 LIONS clinical trial.

Negatives

• Repare Therapeutics will cease to be a publicly traded company, leading to the delisting of its common shares from Nasdaq.
• The company will no longer report initial topline safety, tolerability, and early efficacy data from the POLAR trial for RP-3467 due to the definitive agreement.
• The net loss for the nine months ended September 30, 2025, was $43.5 million, indicating continued operational losses over the longer term.
• Revenue from collaboration agreements for the nine months ended September 30, 2025, was $11.9 million, a significant decrease from $53.5 million for the same period in 2024.

Risks

• The completion of the Transaction on anticipated terms and timing, including obtaining required shareholder and court approvals, and the satisfaction of other conditions to the completion of the Transaction.
• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty, or their respective directors or officers.
• Significant transaction costs and unknown liabilities associated with the Transaction.
• The Company's plans or ability to enter into, or complete, any potential transactions to license or dispose of its product candidates and/or intellectual property related to its RP-3467 and Polq program, RP-1664 program, RP-3500 (Camonsertib) program, and/or other product candidates and research programs.

Future Outlook

The transaction is expected to close in the first quarter of 2026, after which Repare will become a privately held company and its shares will be delisted. Shareholders will receive CVRs, allowing for participation in future proceeds from existing partnerships and potential new licenses or dispositions of product candidates and intellectual property for up to 10 years post-closing. Repare continues efforts to license or dispose of its product candidates and intellectual property prior to closing, which could increase the cash payment to shareholders.

Management Comments

• "Following a thorough and wide-ranging strategic review of potential opportunities, partnerships and transactions aimed at maximizing shareholder value, Repare's Board of Directors has unanimously determined that the Transaction is in the best interests of Repare and its various stakeholders."
• "The Transaction provides a cash payment to shareholders and the opportunity for continued participation in milestones and royalties from existing and potential future partnerships."
• "On behalf of the Company, I would like to acknowledge and thank our employees for their dedication and exceptional service."

Industry Context

This acquisition by a non-profit biotechnology company, XenoTherapeutics, suggests a strategic shift for Repare's assets, potentially moving them into a different development or access model outside of traditional for-profit public company structures. The inclusion of CVRs is a common mechanism in biotech acquisitions to bridge valuation gaps and allow selling shareholders to participate in future upside, especially for clinical-stage assets with uncertain future value. The continued efforts to monetize other pipeline assets prior to closing indicate a focus on maximizing immediate shareholder value before the company goes private.

Comparison to Industry Standards

• The cash component of US$1.82 per share, combined with CVRs, is a common structure in biotech acquisitions, particularly for companies with early-stage or clinical-stage assets where future value is highly dependent on development success and commercialization. This structure is similar to deals seen with companies like Array BioPharma (acquired by Pfizer) or Loxo Oncology (acquired by Eli Lilly), where CVRs were used to provide contingent payments based on regulatory approvals or sales milestones for specific drugs.
• The deal protection provisions, including a non-solicitation covenant and a right to match a superior proposal, are standard in M&A agreements to ensure deal certainty, comparable to those in other public company acquisitions.
• The unanimous recommendation by an independent Transaction Committee and the full Board is a strong indicator of due diligence and perceived fairness, aligning with best practices in corporate governance for such transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive an estimated cash payment of US$1.82 per share and CVRs for potential future proceeds, but will lose public market liquidity and ownership in a publicly traded company.
• Employees: Steve Forte acknowledged and thanked employees for their dedication and service, implying potential changes post-acquisition, though no specifics are given.
• Partners (Bristol-Myers Squibb, Debiopharm, DCx Biotherapeutics): Existing partnerships will continue, with a percentage of net proceeds flowing to CVR holders.
• Regulatory Authorities (SEC, AMF): Will be involved in the filing and review of proxy statements and other transaction-related documents.

Next Steps

• Repare will file a proxy statement on Schedule 14A with the SEC and furnish it to shareholders.
• A special meeting of shareholders will be held to seek required approvals for the transaction.
• The transaction is subject to approval of the Superior Court of Quebec.
• Repare will continue efforts to license or dispose of its product candidates and/or intellectual property (RP-3467, Polq program, RP-1664 program, RP-3500 (Camonsertib) program, and other programs) prior to closing.
• Following completion, Repare will become a privately held company.
• Common shares are expected to be delisted from the Nasdaq Global Select Market.
• Repare will apply to cease to be a reporting issuer under Canadian securities laws and to deregister common shares under the U.S. Securities Exchange Act of 1934.

Key Dates

Recommendation

The definitive agreement for acquisition provides a clear exit strategy for shareholders with an immediate cash component and potential future upside through CVRs. While the Q3 financial results show improvement, the company is still a clinical-stage oncology firm with inherent risks. Given the agreed-upon acquisition terms, the stock price is likely to trade close to the estimated cash value plus the perceived value of the CVRs, making a "hold" recommendation appropriate for existing shareholders awaiting the transaction's close. New investors might find limited upside given the fixed cash component and the speculative nature of CVRs, but the deal provides certainty.

Keywords

Repare Therapeutics, XenoTherapeutics, Acquisition, Merger, Oncology, Biotechnology, Precision Medicine, Synthetic Lethality, RP-1664, RP-3467, CVR, Contingent Value Right, Nasdaq Delisting, Q3 2025 Financials